Sebetralstat

Sebetralstat
Clinical data
Trade names	EKTERLY
Other names	KVD-900, KVD900, Sebetralstat
AHFS/Drugs.com	Ekterly
License data	US DailyMed: Sebetralstat;
Routes of; administration	By mouth, Oral
ATC code	B06AC08 (WHO) ;
Legal status
Legal status	AU: TBD; US: ℞-only; EU: TBD; ℞ (Prescription only);
Identifiers
	IUPAC name N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-[[4-[(2-oxopyridin-1-yl)methyl]phenyl]methyl]pyrazole-4-carboxamide;
CAS Number	1933514-13-6;
PubChem CID	121365142;
IUPHAR/BPS	11947;
DrugBank	DB18305;
ChemSpider	115006749;
UNII	O5ZD2TU2B7;
KEGG	D12396;
ChEMBL	ChEMBL5095248;
Chemical and physical data
Formula	C26H26FN5O4
Molar mass	491.523 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COCC1=NN(C=C1C(=O)NCC2=NC=CC(=C2F)OC)CC3=CC=C(C=C3)CN4C=CC=CC4=O;
	InChI InChI=1S/C26H26FN5O4/c1-35-17-22-20(26(34)29-13-21-25(27)23(36-2)10-11-28-21)16-32(30-22)15-19-8-6-18(7-9-19)14-31-12-4-3-5-24(31)33/h3-12,16H,13-15,17H2,1-2H3,(H,29,34); Key:KGMPDQIYDKKXRD-UHFFFAOYSA-N;

Sebetralstat is an oral on-demand therapy to treat acute hereditary angioedema (HAE) attacks. It is designed to reduce the severity and duration of HAE attacks by inhibiting plasma kallikrein, an enzyme that plays a key role in swelling during HAE attacks. Sebetralstat is marketed under the brand name EKTERLY and was approved by the U.S. Food and Drug Administration (FDA) in July 2025 for use in adults and children aged 12 years of age and older. It represents the first orally administered treatment option for acute HAE attacks.^[1]^[2]

^ "EKTERLY United States Prescribing Information V1.0 Approved" (PDF). www.kalvista.com. 7 July 2025. Retrieved 23 July 2025.
^ "KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema". www.kalvista.com. 7 July 2025. Retrieved 23 July 2025.

[prescribing-information-1] "EKTERLY United States Prescribing Information V1.0 Approved" (PDF). www.kalvista.com. 7 July 2025. Retrieved 23 July 2025.

[Kalvista_press_release-2] "KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema". www.kalvista.com. 7 July 2025. Retrieved 23 July 2025.

[1]

[2]